[Asthenic disorders in schizophrenia (schizoasthenia) on the model of hypochondriac schizophrenia]. / Astenicheskie rasstroistva pri shizofrenii (shizoasteniya) na modeli ipokhondricheskoi shizofrenii.

OBJECTIVE: To determine the structure and mechanisms of interaction of asthenic disorders with negative and positive psychopathological symptoms in hypochondriac schizophrenia. MATERIAL AND METHODS: The study included male and female patients, aged 17-69 years, with a diagnosis of hypochondriac schizophrenia (F20.80 according to ICD-10) and asthenia symptoms. The main research method was clinical, which was supplemented by pathopsychological examination and the use of psychometric scales (PANSS, SANS, MFI-20,VAS asthenia). RESULTS AND CONCLUSION: Asthenia in case of hypochondriac schizophrenia (schizoasthenia) integrates two unrelated phenomena: «weakness¼ and «exhaustion¼ (intolerance to stress), and also acts within the framework of three psychopathological syndromes: neurotic, senestopathic/hypochondriac and overvalued hypochondria. Asthenia with hypochondriac schizophrenia is a predictor of an unfavorable social and clinical prognosis. Integrating into the structure of the clinical manifestations of hypochondriac schizophrenia, asthenia forms close relationships with positive and negative disorders of the type of «general syndromes¼, but remains outside the categories of both positive and negative symptoms of the disease, thus forming a separate «dimension¼ in the psychopathological space of schizophrenia.

[The use of the concentrate of nucleus containing cells of umbilical cord blood for treatment of asthenic disorders (schizoasthenia) in patients with schizophrenia with negative symptoms]. / Primenenie kontsentrata iadrosoderzhashchikh kletok pupovinnoi krovi u bol'nykh s astenicheskimi rasstroistvami (shizoasteniia) v ramkakh shizofrenii, protekaiushchei s preobladaniem negativnykh rasstroistv.

AIM: To assess the safety and efficacy of umbilical cord blood (UCB) cells in the treatment of schizoasthenia and comorbid negative disorders. MATERIAL AND METHODS: The study was conducted in men (n=15) with remission of schizophrenia with a predominance of asthenic disorders (ICD-10 items F20.6 and F21.5). Patients received intravenous infusions of UCB cells at the average dose of 250 mln viable cells per infusion (4 injections at 2 week intervals). The efficacy and safety were assessed using the Positive and Negative Symptoms of Schizophrenia (PANSS), the General Clinical Impression Scale (CGI), Asthenia Scale MFI-20 3, the MATRIX Consensus Cognitive Battery (MCCB), the Clinical evaluation of adverse events (side effects). RESULTS AND CONCLUSION: The infusions of UCB cells have a positive effect on asthenic disorders, increase the level of general activity and minimize cognitive impairments. The authors assume that UCB cells potentiate the activity of typical and atypical antipsychotics.